Sakar Healthcare Q2 FY27: Revenue up 52%, margin expands

What Sakar Healthcare reported for the September quarter

Sakar Healthcare Ltd reported a strong set of numbers for the quarter ended September 30, 2026 (Q2 FY27), as per its results statement published on October 23, 2026. Revenue from operations rose sharply year-on-year, and profitability improved on the back of higher EBITDA and an expanded operating margin. The company also reported a large jump in net profit compared with the same quarter last year.

The figures referenced here are reported numbers from the company’s results statement and related reporting excerpts, not management guidance. The company has not published an earnings-call transcript for the quarter, and the presentation does not provide explicit margin outlook or revenue growth guidance.

Revenue growth: strong year-on-year expansion

Revenue from operations for Q2 FY27 stood at ₹87.4161 crore (₹8,741.61 lakh). In the corresponding quarter ended September 30, 2025 (Q2 FY26), revenue from operations was ₹57.5604 crore (₹5,756.04 lakh). That implies an absolute increase of ₹29.8557 crore (₹2,985.57 lakh), described as approximately 51.9% year-on-year growth.

Separate reporting snippets also summarised the quarter as revenue of about ₹87.4 crore, consistent with the revenue-from-operations figure in the results statement. No sales volume or product-wise volume details were explicitly provided in the text.

Profit after tax: net profit rises sharply YoY

Profit after tax (PAT) for Q2 FY27 was reported at ₹11.3069 crore (₹1,130.69 lakh). This compares with ₹4.5398 crore (₹453.98 lakh) in Q2 FY26. Based on the provided figures, the year-on-year change is about 148.9%.

Another summary also described net profit as ₹11.3 crore versus ₹4.5 crore year-on-year, aligning with the reported PAT figures when rounded. The reported improvement in net profit is one of the key takeaways from the quarter.

EBITDA and operating margin: expansion highlighted

From the same quarter’s statement-based calculation, EBITDA was derived as:

• Profit before tax and exceptional items: ₹16.0204 crore (₹1,602.04 lakh)
• Add depreciation: ₹6.6022 crore (₹660.22 lakh)
• Add finance costs: ₹2.0040 crore (₹200.40 lakh)

This yields an EBITDA of ₹24.6266 crore (₹2,462.66 lakh). Using revenue from operations of ₹87.4161 crore, the calculated EBITDA margin works out to approximately 28.17%.

Separately, a “data snapshot” in the provided text cited EBITDA of ₹24.3 crore and an EBITDA margin of 27.85%, compared with 19.74% in Q2 FY26. The difference between 28.17% (statement-based calculation) and 27.85% (snapshot figure) appears to be a rounding or definition difference in the sources presented, but both indicate a meaningful year-on-year expansion.

What the company and reports attributed the performance to

The provided reporting excerpts attributed the quarter’s improvement to a combination of operational and market drivers. These included oncology approvals, global demand, a stronger oncology mix, operating leverage, and cost management.

In addition, the “recent developments” section noted that Sakar Healthcare submitted un-audited financial results and an investor presentation for the preceding quarter ended June 30, 2026, outlining its contract development and manufacturing services (CDMO) setup and oncology platform strategy. The text does not provide quantified contribution from these initiatives for Q2 FY27.

Standalone vs consolidated references in the provided material

The revenue-from-operations and supporting comparisons were described as coming from consolidated unaudited results (Page 9) and standalone results (Page 2 and Page 9) in the referenced material. The same overall quarterly headline figures were also reported as consolidated net profit of ₹11.30 crore and revenue rising to ₹87.41 crore from ₹57.56 crore.

Because the supplied content includes both “standalone” phrasing and “consolidated” phrasing in different places, the safest reading is that the quarter’s headline performance was consistently reported around the same rounded values, while the underlying source pages may contain both standalone and consolidated presentations.

Quick comparison with earlier quarters shown in the dataset

A quarterly table in the provided text showed “Net Sales Turnover” of ₹72.97 crore for the June 2026 quarter (Jun’26) and ₹57.56 crore for the September 2025 quarter (Sep’25). It also listed “Profit and Loss for the Year” (PAT) at ₹10.28 crore for Jun’26 and ₹4.54 crore for Sep’25.

These entries provide context that the company had already been reporting higher profitability in the June 2026 quarter compared with the prior year’s September quarter. However, the supplied text does not provide Q2 FY27 net sales turnover in that specific table format, so the primary Q2 FY27 revenue reference remains the ₹87.4161 crore “revenue from operations” figure.

Key numbers table: Q2 FY27 vs Q2 FY26 (as reported)

EBITDA bridge table: how the statement-derived EBITDA was computed

Guidance and disclosures: what was not provided

The supplied text explicitly notes that the presentation does not state any margin outlook or guidance. It also notes there is no explicit outlook or forecast for future revenue or volume growth. In addition, the company has not published an earnings-call transcript for this quarter, which limits the availability of management commentary beyond the reported filing.

Why the quarter matters for investors tracking operating efficiency

The most consequential change in the Q2 FY27 data is the combination of higher revenue and stronger operating profitability. The reported expansion in EBITDA margin to the high-20% range (based on the figures provided) indicates improved operating leverage compared with the prior year’s margin of 19.74% cited in the snapshot.

At the same time, with no stated outlook, investors will likely rely on subsequent filings and disclosures to assess whether the oncology mix, approvals-led momentum, and cost actions remain sustained. The next formal update would typically come with future quarterly results and any accompanying presentation materials.

Conclusion

Sakar Healthcare’s Q2 FY27 results statement showed 51.9% year-on-year revenue growth to ₹87.4161 crore and a sharp rise in PAT to ₹11.3069 crore, alongside higher EBITDA and improved operating margin. The company has not provided explicit forward guidance in the supplied material, so the focus stays on reported execution and the next set of regulatory updates.